HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (27) Citing Articles via Google Scholar Google Scholar Articles by Birrell, M.A. Articles by Belvisi, M.G. Search for Related Content PubMed PubMed Citation Articles by Birrell, M.A. Articles by Belvisi, M.G.

PPAR- agonists as therapy for diseases involving airway neutrophilia

¹ Respiratory Pharmacology Group, Cardiothoracic Surgery, The National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK. ² Glaxosmithkline, Respiratory and Inflammatory Centre of Excellence for Drug Discovery, King of Prussia, PA, USA

CORRESPONDENCE: M.G. Belvisi, Respiratory Pharmacology, Cardiothoracic Surgery, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, SW3 6LY, UK. Fax: 44 2073518173. E-mail: m.belvisi@imperial.ac.uk

Keywords: Colony stimulating factors, murine, neutrophils, peroxisome proliferator-activated receptors

Received: August 28, 2003
Accepted March 14, 2004

This work was supported by the Harefield Research Foundation and a grant from the Clinical Research Committee, Royal Brompton and Harefield Hospital Trust.

Peroxisome proliferator-activated receptors (PPARs) are a family of ligand-activated nuclear hormone receptors belonging to the steroid receptor superfamily. Previously, the present authors have shown that PPAR- agonists inhibit the release of inflammatory cell survival factors and induce apoptosis in vitro. The aim of this study was to determine the effect of two structurally different PPAR agonists in an in vivo model of lipopolysaccharide (LPS)-induced airway inflammation.

Mice were treated with PPAR agonists, rosiglitazone or SB 219994, prior to exposure to aerosolised LPS, and the extent of airway inflammation was assessed 3 h later.

In these experiments, the PPAR ligands inhibited LPS-induced airway neutrophilia and associated chemoattractants/survival factors (keratinocyte-derived chemokine and granulocyte-colony stimulating factor) in the mouse lung.

The present authors postulate that if a peroxisome proliferator-activated receptor agonist has the same effect in man, and neutrophils are important in the progression of respiratory diseases, such as chronic obstructive pulmonary disease, then this class of compounds could be a potential therapy. Furthermore, several peroxisome proliferator-activated receptor- agonists have been shown to be clinically effective for the treatment of type II diabetes, suggesting that any benefit of peroxisome proliferator-activated receptor- ligands in the progression of respiratory diseases, which may involve airway neutrophilia, could be explored relatively quickly.

This article has been cited by other articles:

				M. G. Belvisi and D. J. Hele Peroxisome Proliferator-Activated Receptors as Novel Targets in Lung Disease Chest, July 1, 2008; 134(1): 152 - 157. [Abstract] [Full Text] [PDF]

				S. M. Saleh, T. S. Mann, T. Peters, R. J. Betts, and P. J. Henry Influence of Dexamethasone on Protease-Activated Receptor 2-Mediated Responses in the Airways J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 622 - 630. [Abstract] [Full Text] [PDF]

				P. S. D. Weber, S. A. Madsen-Bouterse, G. J. M. Rosa, S. Sipkovsky, X. Ren, P. E. Almeida, R. Kruska, R. G. Halgren, J. L. Barrick, and J. L. Burton Analysis of the bovine neutrophil transcriptome during glucocorticoid treatment Physiol Genomics, December 13, 2006; 28(1): 97 - 112. [Abstract] [Full Text] [PDF]

				K. McCluskie, U. Klein, C. Linnevers, Y.-h. Ji, A. Yang, C. Husfeld, and G. R. Thomas Phosphodiesterase Type 4 Inhibitors Cause Proinflammatory Effects in Vivo J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 468 - 476. [Abstract] [Full Text] [PDF]

				D. M. Simon, M. C. Arikan, S. Srisuma, S. Bhattacharya, L. W. Tsai, E. P. Ingenito, F. Gonzalez, S. D. Shapiro, and T. J. Mariani Epithelial cell PPAR{gamma} contributes to normal lung maturation FASEB J, July 1, 2006; 20(9): 1507 - 1509. [Abstract] [Full Text] [PDF]

				E. Marian, S. Baraldo, A. Visentin, A. Papi, M. Saetta, L. M. Fabbri, and P. Maestrelli Up-Regulated Membrane and Nuclear Leukotriene B4 Receptors in COPD Chest, June 1, 2006; 129(6): 1523 - 1530. [Abstract] [Full Text] [PDF]

				S. C.W. Tang, J. C.K. Leung, L. Y.Y. Chan, A. W.L. Tsang, and K. N. Lai Activation of Tubular Epithelial Cells in Diabetic Nephropathy and the Role of the Peroxisome Proliferator-Activated Receptor-{gamma} Agonist J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1633 - 1643. [Abstract] [Full Text] [PDF]